ClinicalTrials.gg
Enrolling by invitationNCT04363047Updated May 8, 2024

Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19

An observational study in SARS Virus, sponsored by University of Manchester. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by University of Manchester · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
125
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Severe Acute Respiratory Syndrome with a site in United Kingdom — 2 open to participants now, 2 under way, 1 of them phase 3. Severe Acute Respiratory Syndrome · United Kingdom.

Planned enrollment
5th of 11
125 · median 105
Started
2020
with 14 others
Observational
11 of 24
1 open now
Registered
4th of 24
by date

Among the 24 studies in Severe Acute Respiratory Syndrome with a site in United Kingdom, this one is the 5th largest by planned enrollment of the 11 observational ones that give a count, is one of 15 that started in 2020, is one of 11 observational ones, and was the 4th registered.

Severe Acute Respiratory Syndrome

376 studies on the registry are indexed under Severe Acute Respiratory Syndrome; 14 are open to participants now.

Browse Severe Acute Respiratory Syndrome studies →

Open to participants now

2 of the 24 studies in Severe Acute Respiratory Syndrome with a site in United Kingdom are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 7 Severe Acute Respiratory Syndrome studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Severe Acute Respiratory Syndrome with a site in United Kingdom, or all of them as a file.
02

Study summary

A team at the University of Manchester are developing a test that tcould be helpful in detecting immunity to the Coronavirus (which causes the COVID-19 disease) in participants with inflammatory arthritis. It is based on a flu assay has already developed; the team will replace the flu antigen with a Coronavirus antigen to see if it is effective.

This project aims to develop a test to see if people who have had the virus have developed immunity to it. This could help to predict who might or might not get the disease a second time, who should stay at home to be protected from potential infection or who will not develop any symptoms, even if exposed to the virus.

When vaccination trials against the Coronavirus will be launched, this test could also help to see if the vaccine is effective.

03

Conditions studied

  • SARS Virus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

People who have previously taken part in (and provided at least 1 set of blood samples to) either the BRAGGSS or National Repository Healthy Volunteer Studies and have given us permission to contact them for future research

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has previously taken part in either the BRAGGSS or National Repository Healthy Volunteer Study
  • Has agreed to be contacted abut future research projects
  • Has previously provided a blood sample for either the BRAGGSS or National Repository Healthy Volunteer Study
  • Is willing to complete the form, registration slip, questionnaire and provide a 40ml blood sample
  • Has a good written understanding of English

Exclusion criteria

Exclusion Criteria:

  • Has not previously taken part in either the BRAGGSS or National Repository Healthy Volunteer Study
  • Has not agreed to be contacted abut future research projects
  • Has not previously provided a blood sample for either the BRAGGSS or National Repository Healthy Volunteer Study
  • Is not willing to complete the form, registration slip, questionnaire and provide a 40ml blood sample
  • Has not got a good written understanding of English
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
125 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Healthy Volunteers

    These people will have already provided at least one sample as part of the National Repository Healthy Volunteer Study. We aim to take blood samples from participants who have recovered from COVID-19 and compare them with blood samples we already have which were taken before the COVID-19 pandemic. We will need to compare these samples to other samples, so we will also need to blood samples from people who have not had COVID-19 (who have either tested negative or never had any symptoms).

    Other: 40ml blood sample

  • Rheumatoid Arthritis

    These people will have already provided at least one sample as part of the BRAGGSS Study. We aim to take blood samples from participants who have recovered from COVID-19 and compare them with blood samples we already have which were taken before the COVID-19 pandemic. We will need to compare these samples to other samples, so we will also need to blood samples from people who have not had COVID-19 (who have either tested negative or never had any symptoms).

    Other: 40ml blood sample

Interventions

  • Other40ml blood sample

    We'll be collecting cells, DNA and serum.

06

What researchers measure

Primary outcomes

  1. Prevalence and abundance of CD4+ T lymphocytes

    the prevalence and abundance of CD4+ T lymphocytes specifically recognizing SARS-CoV-2 in COVID-19 patients with inflammatory arthritis, in pre- and post-infection samples; in patients without COVID-19 and in healthy volunteers with or without COVID-19. Correlation of these cells with COVID-19 severity.

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2020 (actual). Primary completion is estimated for Jul 2026, 69 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2020
First posted
Apr 27, 2020
StartActual
Oct 1, 2020
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jul 31, 2026
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04363047
Responsible party
Dr. Sebastien Viatte (Lecturer in Genetics, University of Manchester) — Principal investigator
First posted
Apr 27, 2020
Start date
Oct 1, 2020
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
May 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion